NewzITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two prominent companies operating within the growing radiopharmaceuticals sector, have agreed to a merger valued at at least $1.65 billion. The transaction involves Telix acquiring all shares of the privately held ITM.
In addition to the baseline valuation of at least $1.65 billion, the agreement includes potential additional payments of $700 million contingent upon certain conditions. The consolidation of these two leading entities comes following a surprise FDA rejection received by one of the companies.
In-depth summary · AI, neutral